Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells.
about
Gene Therapy Applications to Cancer TreatmentMechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells.Molecular engineering of viral gene delivery vehiclesDefining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction In Vitro in the Presence of Mouse Serum.Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature.A strategy for adenovirus vector targeting with a secreted single chain antibody.Infection and killing of multiple myeloma by adenovirusesLinked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenovirusesRetargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX.Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds.Development of viral vectors for use in cardiovascular gene therapy.Reduced infectivity of adenovirus type 5 particles and degradation of entering viral genomes associated with incomplete processing of the preterminal protein.Novel vectors for in vivo gene delivery to vascular tissue.Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.Flexibility of the adenovirus fiber is required for efficient receptor interaction.Redirecting adenovirus tropism by genetic, chemical, and mechanical modification of the adenovirus surface for cancer gene therapy.Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization.Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.Oncolytic Viral Therapy for Mesothelioma.Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer.Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy.Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation.Role of cell surface molecules and autologous ascitic fluid in determining efficiency of adenoviral transduction of ovarian cancer cells.Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.Designer Oncolytic Adenovirus: Coming of Age.
P2860
Q24792808-141A6935-E764-420F-99C4-128AF5DDAD53Q33275292-9FE6DAA3-E83C-44D4-AF18-329708D51029Q33353795-E9B8F292-8998-41D3-A354-CB9A82541635Q33440718-E145B43C-AD43-4D29-ACA7-6828E3F4B0C5Q33456433-6E446F91-7DD3-4D3E-99FF-43AF766C9981Q33520212-E920DA4D-965C-4009-89DA-B51E68648C7EQ33691833-A764D49A-D3B8-4CC7-A78A-885CA46916AEQ33755007-F1BBCF1C-BC06-4007-8EBF-23DDF37B5692Q34120709-C042FBA2-7C7D-468F-9154-2933D5B1D558Q34297058-4DCD5ECC-05FB-46A0-9896-D972F99AE6D1Q35156188-C80365EB-DCB3-447E-80F1-3AE52BF9F8F6Q35260617-B1FA1468-5CD9-40D7-904B-A644A746EC44Q36414237-2B8BE8CD-39BA-4155-93A0-A9E1304C7264Q36842711-B327C0C2-2C63-4779-A9BE-E1C8EABBDD5BQ37227135-8544729C-DC3F-4FA3-BD3E-8F59FB267B40Q38353615-E1B02A1D-46C4-4725-BACF-C833E157E6D9Q38769919-2396F6D9-AB22-45BC-9EAF-640A6596FD2DQ39682554-32ACC636-79D3-48CA-83BF-FF7A1DC73829Q39682744-66854853-E2E2-47D0-B4EA-61E3377F9A6BQ40051845-1CF6AFF7-674D-4BDB-8A9A-E846FE01DE4EQ40055106-AC5CBACB-D45E-49C2-9680-29AFAD60527AQ40189728-FAA914FD-3395-4130-9FB6-ACA1C1707780Q40369834-1E0278F8-3299-4861-90DB-C0FF391EF6E7Q40672499-74B38219-1EDD-4D45-9BEB-B68EB685E99DQ43030471-DE560004-0CFB-42E8-91C7-95C2CE3F9934Q47251747-1D3187DF-1B19-4AD5-B974-4F861143606EQ55467684-66E50F5B-1535-4CA9-9579-F9B061EF9FA7
P2860
Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Adenovirus type 5 viral partic ...... ovirus receptor-bearing cells.
@ast
Adenovirus type 5 viral partic ...... ovirus receptor-bearing cells.
@en
type
label
Adenovirus type 5 viral partic ...... ovirus receptor-bearing cells.
@ast
Adenovirus type 5 viral partic ...... ovirus receptor-bearing cells.
@en
prefLabel
Adenovirus type 5 viral partic ...... ovirus receptor-bearing cells.
@ast
Adenovirus type 5 viral partic ...... ovirus receptor-bearing cells.
@en
P2093
P2860
P1433
P1476
Adenovirus type 5 viral partic ...... ovirus receptor-bearing cells.
@en
P2093
Hallenbeck PL
Jakubczak JL
Nemerow GR
Rollence ML
Stevenson SC
Stewart DA
Von Seggern DJ
P2860
P304
P356
10.1128/JVI.75.6.2972-2981.2001
P577
2001-03-01T00:00:00Z